Clinical Trials

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma


Study ID
Celgene CC-220-MM-001

NCT Number
NCT02773030 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0052

Principle Investigator
Dr. David Siegel

Phase
I/II

Sponsor
Celgene


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now